Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells that can invade tissues and metastasize to distant organs.
The global radiopharmaceuticals market is projected to reach $12.8B–$21.8B by 2033–2036, driven by cancer therapy demand. Oncology accounts for over 50% of applications, Technetium-99m dominates radioisotopes, and Asia-Pacific leads growth.
Maharashtra will add immunotherapy and PET scans to its state health scheme and open 27 new cancer centres. Separately, the ICMR has issued national guidelines for lung cancer treatment including immunotherapy protocols, as MPs push for expanded access.
Johnson & Johnson faces new talc verdicts in Minnesota and Pennsylvania totaling over $10 million, with 67,000+ lawsuits pending. Meanwhile, the FDA approved a new monthly dosing for RYBREVANT FASPRO, and the company launched its Shockwave C2 Aero coronary catheter globally.
An experimental study found remote ischemic conditioning protected the heart during anthracycline treatment in tumor-bearing mice without reducing antitumor efficacy. The work supports the ongoing RESILIENCE clinical trial in cancer patients.
Compugen said it will release fourth quarter and full year 2025 results on March 2, 2026, and present at the Needham Virtual Healthcare Conference on April 13. The company also outlined its Phase 1 and Phase 3 immuno-oncology pipeline programs.
Research and Markets added two cell and gene therapy publications, including a tools and reagents market report forecasting growth from $12 billion in 2025 to $19.8 billion by 2030. The reports track approvals, financing, deals, and manufacturing developments.
MSD said sacituzumab tirumotecan improved overall survival and progression-free survival in the Phase III TroFuse-005 trial in endometrial cancer. The study also met its objective response rate endpoint.
Only 17.7% of pediatric anticancer drugs advance to phase 3 trials, and just 12% earn FDA approval within 10 years, compared to 38.7% for adult drugs. The pace of pediatric approvals has accelerated recently, but funding and market size constraints remain.
Biotech M&A is shifting toward late-stage CNS and oncology assets with human clinical validation. Oncotelic Therapeutics said it advanced global IP protection for OT-101 and CNS drug delivery.
Microgravity drug research is expanding from ISS crystal studies to commercial manufacturing efforts. New experiments and a Varda-United Therapeutics collaboration target improved drug stability, delivery and production.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07601802 |
Acute Risk Monitoring for Oncology Therapy Regimen |
COMPLETED | |
| NCT07600294 |
Integrated Cancer Services in Thailand: A Prototype for Excellence |
COMPLETED | NA |
| NCT07598851 |
Virtual Reality Education for Radiation Therapy Patients |
COMPLETED | NA |
| NCT07598747 |
Prospective Study for the Development, Validation and Confirmation of a Multi-Cancer Early Detection Platform Through Whole-Genome Sequencing Analysis of Circulating DNA in Cancer and Non-Cancer Subjects |
RECRUITING | |
| NCT07588607 |
Social Media Posts About Cancer: Five Timepoints |
COMPLETED | NA |
| NCT07585838 |
Hope-Focused Motivational Interviewing in Cancer Patients |
ENROLLING_BY_INVITATION | NA |
| NCT07584824 |
Is the 1939 Cancer Act Fit for Purpose in the Modern Technology Era? |
RECRUITING | |
| NCT07583069 |
Psychosocial Effects of a Trauma-Informed Artificial Intelligence-Supported Chatbot in Adults Newly Diagnosed With Cancer |
NOT_YET_RECRUITING | NA |
| NCT07581080 |
Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study |
RECRUITING | NA |
| NCT07578571 |
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer |
RECRUITING | PHASE1 |
